中华实验外科杂志
中華實驗外科雜誌
중화실험외과잡지
CHINESE JOURNAL OF EXPERIMENTAL SURGERY
2014年
3期
644-646
,共3页
大肠腺癌%肺癌肿瘤抑制因子%基因甲基化
大腸腺癌%肺癌腫瘤抑製因子%基因甲基化
대장선암%폐암종류억제인자%기인갑기화
Colorectal adenocarcinama%Tumor suppressor in lung cancer-1%Gene methylation
目的 检测大肠腺癌中肺癌肿瘤抑制因子-1(TSLC-1)的表达及其基因的甲基化状态,探讨其临床意义.方法 用免疫组织化学Envision二步法检测大肠癌组织中TSLC-1蛋白的表达,分析其表达与临床病理参数和预后的相关性,甲基化特异性聚合酶链反应(MSP)检测TSLC-1基因的甲基化状态.结果 癌旁正常肠黏膜与大肠腺癌的TSCL-1表达阳性率分别为100％(20/20)和 41.51％ (22/53),差异有统计学意义(P＜0.05).大肠腺癌中,TSLC-1表达阴性组具有更高的淋巴结转移率和临床分期(P ＜0.05);TSLC-1表达阴性组的平均生存时间为32.22个月,明显低于TSLC-1表达阳性组(平均生存时间为47.55个月,P＜0.05);TSLC-1表达阴性组中TSLC-1基因的甲基化检出率为41.94％(13/31),明显高于TSLC-1表达阳性组[9.09％(2/22)]及癌旁正常黏膜组[5.00％ (1/20),P＜0.05].结论 TSLC-1在大肠腺癌中表达下降,对预后的判断具有重要的参考价值,其基因的甲基化可能是大肠腺癌TSLC-1表达下调的重要机制.
目的 檢測大腸腺癌中肺癌腫瘤抑製因子-1(TSLC-1)的錶達及其基因的甲基化狀態,探討其臨床意義.方法 用免疫組織化學Envision二步法檢測大腸癌組織中TSLC-1蛋白的錶達,分析其錶達與臨床病理參數和預後的相關性,甲基化特異性聚閤酶鏈反應(MSP)檢測TSLC-1基因的甲基化狀態.結果 癌徬正常腸黏膜與大腸腺癌的TSCL-1錶達暘性率分彆為100％(20/20)和 41.51％ (22/53),差異有統計學意義(P＜0.05).大腸腺癌中,TSLC-1錶達陰性組具有更高的淋巴結轉移率和臨床分期(P ＜0.05);TSLC-1錶達陰性組的平均生存時間為32.22箇月,明顯低于TSLC-1錶達暘性組(平均生存時間為47.55箇月,P＜0.05);TSLC-1錶達陰性組中TSLC-1基因的甲基化檢齣率為41.94％(13/31),明顯高于TSLC-1錶達暘性組[9.09％(2/22)]及癌徬正常黏膜組[5.00％ (1/20),P＜0.05].結論 TSLC-1在大腸腺癌中錶達下降,對預後的判斷具有重要的參攷價值,其基因的甲基化可能是大腸腺癌TSLC-1錶達下調的重要機製.
목적 검측대장선암중폐암종류억제인자-1(TSLC-1)적표체급기기인적갑기화상태,탐토기림상의의.방법 용면역조직화학Envision이보법검측대장암조직중TSLC-1단백적표체,분석기표체여림상병리삼수화예후적상관성,갑기화특이성취합매련반응(MSP)검측TSLC-1기인적갑기화상태.결과 암방정상장점막여대장선암적TSCL-1표체양성솔분별위100％(20/20)화 41.51％ (22/53),차이유통계학의의(P＜0.05).대장선암중,TSLC-1표체음성조구유경고적림파결전이솔화림상분기(P ＜0.05);TSLC-1표체음성조적평균생존시간위32.22개월,명현저우TSLC-1표체양성조(평균생존시간위47.55개월,P＜0.05);TSLC-1표체음성조중TSLC-1기인적갑기화검출솔위41.94％(13/31),명현고우TSLC-1표체양성조[9.09％(2/22)]급암방정상점막조[5.00％ (1/20),P＜0.05].결론 TSLC-1재대장선암중표체하강,대예후적판단구유중요적삼고개치,기기인적갑기화가능시대장선암TSLC-1표체하조적중요궤제.
Objective To investigate the expression of tumor suppressor in lung cancer-1 (TSLC-1) and its gene promoter methylation in colorectal adenocarcinoma,and evaluate its clinical signifi-cance.Methods Immunohistochemical Envision two-step technique was used to detect the expression of TSLC1 in primary colorectal adenocarcinoma; and the relationships between the expression of TSLC1 and clinical parameter including prognosis were analysed statistically.The promoter methylation of TSLC1 gene was detected by methylation-specific polymerase chain reaction.Results TSLC-1 protein expressing positive rate in primary colorectal adenocarcinoma was 41.51％ (22/53),which was obviously lower than that in paraneoplastic colorectal mucous (100％,20/20).Compared with TSLC-1 positive expressing group,group of TSCL-1 negative expressing showed higher lymph node metastasis rate and more advanced clinical stage (P ＜ 0.05).The median survival time in TSLC-1 negative expressing group was 32.22 months,significantly shorter as compared with TSLC-1 positive expressing group (47.55 months) (P ＜ 0.05).TSLC-1 gene promoter region was methylated in 13 of 31 (41.94％) colorectal adenocarcinomas without TSLC-1 protein expressing,that was higher significantly than that in the group of TSLC-1 protein positive expressing (2/22) and normal tissue adjacent to cancer (1/20) (P ＜ 0.05).Conclusion TSLC-1 protein expression was down-regulated in primary colorectal adenocarcinoma,and it was an important factor for predicting prognosis; the methylation-mediated inactivation of TSLC-1 maybe is main mechanism of TSLC-1 expressing down-regulation.
